Johnson & Johnson Innovative Medicine

NEWS: Today we officially break ground on our new biologics manufacturing facility in Wilson, North Carolina. This 500,000 square foot state-of-the-art facility will create more than 5,000 high-wage manufacturing and construction jobs while helping to deliver transformational medicines for people living with cancer, immune-mediated, and neurological diseases. Learn more about the new site and our investment: https://bit.ly/4bOMjxB #JNJSupplyChain #Manufacturing

Wonderful news for this patient community. #JNJImmunology

#NEWS: The FDA has approved our advanced therapy for adults with moderately to severely active Crohn’s disease with both subcutaneous and intravenous induction options, offering more choice for patients. Learn how this approval underscores our decades-long commitment to innovation that meets the individualized needs of people with inflammatory bowel disease (IBD): https://lnkd.in/eJ_mkRMW #JNJImmunology

At Johnson & Johnson, we’re not just developing new therapies, we’re working to change lives. We’re excited to share new data on our targeted therapy for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) at the 2025 European Lung Cancer Congress (ELCC). Every breakthrough brings us one step closer to shaping the future of #LungCancer care: https://lnkd.in/euBmNQdC #JNJOncology #ELCC25 #NSCLC

We believe that a great idea can come from anywhere, including you! We’re seeking novel approaches to modulating intestinal barrier function and integrity towards achieving epithelial barrier homeostasis and healing, including approaches to preventing or repairing epithelial damage, and methods for assessing barrier function/dysfunction.?? ?? To share your idea, apply today for our Pitching Gastroenterology Advancements QuickFire Challenge.?Innovators with the most promising ideas will have a chance to showcase their science, either in person or virtually, to a panel of Johnson & Johnson leaders during the 2025 Digestive Disease Week? (DDW) Conference in San Diego, CA, May 3-6, 2025.?? ?? Apply by April 11 to be considered: https://lnkd.in/e6kkCqRv #QuickFireChallenge #JNJImmunology?

Today, we’re excited to announce that the U.S. FDA has granted Fast Track designation to our investigational therapy with the potential to treat people living with Sj?gren’s disease (SjD). This designation represents an important step forward in our efforts to bring meaningful advancements to our patients. Around four million people worldwide live with SjD, and there are currently no approved advanced treatment options indicated for SjD. We are driven by the urgency to provide proven and targeted options for patients who live with debilitating symptoms affecting their day-to-day lives. Read more: https://lnkd.in/eTmbcu8h #JNJImmunology

Cell therapy is a cutting-edge treatment option for patients with difficult-to-treat cancers. We are committed to harnessing the best science to advance the blood cancer treatment landscape. Our ongoing innovation in cell therapy plays a critical role in helping to improve options and broaden access to treatments for patients globally: https://lnkd.in/eCKwpj3u #JNJOncology

Having #MultipleMyeloma (MM) may increase the chances of developing light chain Amyloidosis (AL), a rare disease characterized by a buildup of abnormal amyloid deposits in the body.?? ? March is #AmyloidosisAwarenessMonth. At Johnson & Johnson, we are encouraged by the advances in research and innovation in treatments for patients with MM and AL.?? ? We are committed to delivering life-changing therapies to address unmet patient needs and get #InFrontofCancer: https://lnkd.in/eBnYyKpd?? ? #JNJOncology #MyelomaActionMonth #MyelomaMilestones?

The standard of care in certain kinds of bladder cancer hasn’t significantly changed in 40 years. Many patients may face life-altering surgical options such as radical cystectomy, or complete bladder removal when cancer recurs. With the treatment landscape evolving, education and open dialogue between physicians and patients will be crucial to navigate the complexities of care. https://lnkd.in/e2pfrcN7

Navigating a pregnancy affected by hemolytic disease of the fetus and newborn (HDFN) - a rare condition where maternal antibodies attack fetal red blood cells - can feel overwhelming and scary. As we come together for World Alloimmunization and HDFN Awareness Day, we recognize the families impacted by this difficult disease and champion those dedicated to addressing this critical unmet need. At #PatientsasPartners2025 next week, we’re discussing how patient insights are enhancing clinical trials and accelerating discovery. You can read about our commitment to advancing therapies for #HDFN on STAT: https://lnkd.in/e25sMJkE #MaternalFetalHealth #EmpoweredInPurple #JNJImmunology